Royalty Pharma Investor Relations Material
Latest events
M&A Announcement
Royalty Pharma
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Royalty Pharma plc
Access all reports
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. The company's royalty acquisition segment engages in the acquisition of royalty streams from pharmaceutical companies. Its funding segment provides equity or loan financing to biotechnology companies developing innovative methods for the treatment of cancer, inflammatory disease, obesity, diabetes, and other metabolic disorders.
Key slides for Royalty Pharma plc
43rd Annual J.P. Morgan Healthcare Conference 2025
Royalty Pharma plc
Q3 2024
Royalty Pharma plc
Latest articles
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
The Evolution of the IRO Role: Staying Informed and Strategic With Quartr Pro
Staying informed is critical for IROs. Quartr Pro simplifies gathering market insights and narrative positioning with unprecedented speed and precision.
3 Feb 2025
Mips: The Gore-Tex of Brain Protection
How Mips turned a critical safety flaw into a global success, redefining helmet protection with its technology and ingredient brand business model.
24 Jan 2025
Ticker symbol
RPRX
Country
🇺🇸 United States